GE MEDICAL SYSTEMS

FDA grants 510(k) clearance for an automated Monte Carlo dosimetry method, enabling rapid radiotherapy dose planning in seconds via the MIM SurePlan MRT platform. This advancement allows for quicker, more accurate patient-specific dosimetry, potentially improving radiopharmaceutical therapy outcomes.

GE HealthCare's MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry using the Dose Planning Method (DPM) in MIM SurePlan MRT, enabling fast, accurate absorbed dose calculation for personalized Theranostics treatments without additional hardware.

The radiopharmaceuticals market was valued at USD 5.0 billion in 2023 and is projected to reach USD 16.6 billion by 2032, growing at a CAGR of 10.4%. The market is driven by increasing cancer cases and advancements in diagnostic and therapeutic radiopharmaceuticals. Technetium-99m dominates the market due to its wide diagnostic applications. North America holds the largest market share, while Asia Pacific is the fastest-growing region. Key players include GE Healthcare, Curium Pharma, and Lantheus.

The article discusses the importance of enabling JavaScript for optimal app performance.

GE HealthCare’s MIM Software received FDA 510(k) clearance for Monte Carlo dosimetry, enabling accurate radionuclide absorbed dose calculations in theranostics, enhancing personalized cancer care.

The Synthesis Modules for Radiotracers Market was valued at USD 1.20 Billion in 2023 and is projected to reach USD 2.27 Billion by 2032, growing at a CAGR of 7.66%. Technological advancements and increased demand for personalized medicine drive market growth.

Siemens Healthineers received premarket approval for the 3D portion of its Mammomat B.brilliant mammography platform, featuring 50-degree wide-angle technology for faster, more accurate breast imaging. The system aims to improve detection of abnormalities and microcalcifications, with a scan time 35% faster than competitors.

The FDA approved flurpiridaz F-18, a new PET tracer for myocardial perfusion imaging, expected to boost PET testing growth. It's the first new cardiac PET radiotracer in decades, with a longer half-life and superior image quality, enhancing diagnostic certainty. This will expand PET use, improve collaboration among cardiologists, and increase patient access to the test.

FDA approves Flyrcado™ for PET MPI in CAD patients; supported by 2 trials with sensitivity 74-89% and specificity 53-86%; common adverse reactions include dyspnea, headache, and angina; longer half-life allows offsite manufacturing and combined stress testing with PET imaging; availability expected in early 2025.